RNA Atrium Therapeutics, Inc.
$8.34
Atrium Therapeutics, Inc. (RNA) Earnings News
Earnings press releases, previews and reviews for Atrium Therapeutics, Inc. (RNA), newest first.
Monday
November 2, 2026
6:30 AM ET
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
Tuesday
October 27, 2026
6:30 AM ET
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
Thursday
October 8, 2026
6:30 AM ET
Atrium Therapeutics Announces $50 Million Private Placement
Thursday
August 13, 2026
4:44 PM ET
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Tuesday
July 14, 2026
6:30 AM ET
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Thursday
May 14, 2026
4:40 PM ET
Atrium Therapeutics Reports First Quarter 2026 Financial Results